Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Race Oncology Ltd. ( (AU:RAC) ) has issued an update.
Racura Oncology and the University of Wollongong have secured funding from the New South Wales Government’s TechVouchers program to investigate the efficacy of (E,E)-bisantrene in BRCA-mutated breast and ovarian cancer models. The collaboration, led by oncology researcher Dr Saurabh Satija, aims to generate preclinical evidence supporting the development of Racura’s RC220 as a targeted therapy for high-risk BRCA-mutation carriers.
The project builds on prior work showing that (E,E)-bisantrene acts as a G-quadruplex stabiliser, a mechanism believed to be particularly effective in BRCA-deficient tumours. Positive preclinical results and planned publication in high-impact journals could strengthen Racura’s scientific validation, enhance its positioning in precision oncology, and ultimately support new treatment options for patients with inherited BRCA mutations.
More about Race Oncology Ltd.
Racura Oncology Ltd is an Australian biotechnology company focused on developing targeted cancer therapies, with a particular emphasis on small-molecule drugs such as (E,E)-bisantrene. The company is advancing candidates like RC220 to address genetically defined patient populations, including those with BRCA-mutated breast and ovarian cancers, where there is significant unmet medical need.
Average Trading Volume: 205,271
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$520.1M
Learn more about RAC stock on TipRanks’ Stock Analysis page.